Walter Boomer, MD
Pulmonary Disease · Tulsa, OKNPI 1578598074
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.9%), education and travel and lodging — rather than concentrated in one kind of arrangement. 53 manufacturers reported payments, led by Intuitive Surgical at 47.1% of the total. Among pulmonary disease clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,072 payments — averaging $39.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$20K
- Pulmonx Corporation$4K
- AstraZeneca$3K
- GSK$2K
- Boehringer Ingelheim$2K
- Grifols USA, LLC$1K
- plus $10K from 47 others
What the payments were for
- Speaking & faculty fees$4,0009%
- Travel & lodging$6,75316%
- Food & beverage$23,85756%
- Education$7,76718%
- Gifts$3171%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$11,481
- DA VINCI SP$4,300
- ION$3,000
- CHARTIS CATHETER$2,035
- ZEPHYR DELIVERY CATHETER$2,035
- ZEPHYR ENDOBRONCHIAL VALVE$2,035
- PULMONX CHARTIS TABLET CONSOLE$2,035
- Spin$247
- VAPOTHERM$233
- FASENRA$212
- SPiN Thoracic Navigation System, 120V, 60Hz$151
- Cios Spin$150
- ALIYA SYSTEM$138
- Endurant$125
- Progel Applicator Spray Tips$123
- Pulmonx Endobronchial Valve EBV$119
- OFEV$118
- DALVANCE$118
- Prolastin-C$112
- BEVESPI AEROSPHERE$107
How this compares
$42,695 in reported general payments places this provider in the 90th percentile of 133 pulmonary disease providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 659 | $492,594 |
| OpsumitMacitentan | 28 | $462,436 |
| OfevNintedanib Esylate | 18 | $255,342 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 226 | $164,925 |
| Breo ElliptaFluticasone/Vilanterol | 347 | $161,195 |
| Spiriva RespimatTiotropium Bromide | 280 | $146,471 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 283 | $35,848 |
| Incruse ElliptaUmeclidinium Bromide | 56 | $24,040 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 38 | $20,831 |
| Spiriva HandihalerTiotropium Bromide | 30 | $18,730 |
| Wixela InhubFluticasone Propion/Salmeterol | 130 | $15,681 |
| SymbicortBudesonide/Formoterol Fumarate | 43 | $15,419 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $9,402 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 366 | $8,006 |
| Fluticasone-VilanterolFluticasone/Vilanterol | 25 | $6,581 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta, Arnuity Ellipta | $2,288 | $703,1971,120 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $654 | $462,43628 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat | $2,218 | $411,215312 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $3,409 | $180,344269 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 133 pulmonary disease providers in Oklahoma.
Other pulmonary disease in Tulsa
- Jennifer BierachTulsa$141K
- Hassan AbouhouliTulsa$103K
- Grace KennedyTulsa$57K
- Emil SchelbarTulsa$20K
- Andrew GottehrerTulsa$16K
- Bradley EdgingtonTulsa$12K
- Habiba HussainTulsa$10K
- Conner MoslanderTulsa$9K
- Pratyaksha SankhyanTulsa$9K
- Priyanka PathaniaTulsa$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.